evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

170 questions · 183 findings · 10 reviews · Gut

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 0.5%GRADE not reported 3 · 1.6%Very low 50 · 27.3%Low 37 · 20.2%Moderate 60 · 32.8%High 32 · 17.5%

Chemotherapy vs placebo, best supportive care (BSC) or no treatment

Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemotherapy showed no clear difference in tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).

1 finding from 1 review

Chemotherapy vs placebo, best supportive care (BSC) or no treatment

Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemotherapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).

1 finding from 1 review

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Overall survival · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy

Summary of findings table (subcomparison 2): second‐line… probably leads to lower overall survival compared with control intervention alone (moderate certainty).

1 finding from 1 review

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy

Summary of findings table (subcomparison 2): second‐line… may leads to lower progression‐free survival compared with control intervention alone (low certainty).

1 finding from 1 review

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Toxicity · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy

It is very uncertain whether summary of findings table (subcomparison 2): second‐line… changes toxicity compared with control intervention alone (very low certainty).

1 finding from 1 review

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Progression‐free survival · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).

1 finding from 1 review

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Overall response rate Duration of · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall response rate Duration of compared with chemotherapy alone (low certainty).

1 finding from 1 review

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Adverse event (any) Duration of · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher adverse event (any) Duration of compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Severe adverse event (grade ≥ 3 ) Duration of · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher severe adverse event (grade ≥ 3 ) Duration of compared with chemotherapy alone (moderate certainty).

1 finding from 1 review